Healthcare policies have rapidly evolved in recent years, and 2025 was no exception. From payment policies to physician shortages, ASE and other medical societies had plenty to fight for throughout the year.
There is a risk that these catheters will fail to retain their shape during use, causing procedure delays and creating the risk of an adverse outcome. The FDA first warned users about the issue back in August.
Sean Clifford filed the lawsuit Sept. 24, 2024, in the New York State Supreme Court, contending a radiologist failed to spot signs of a forthcoming stroke.
As IR procedure volumes continue to climb, coupled with anesthesiology provider shortages, there is growing interest in achieving “deeper, more reliable sedation.”
A new analysis claims the “benchmark” qualifying payment amount insurers calculate often “dramatically” understates the actual median in-network rates they are paying for in-network care.
For years, the agency has packaged payment for nuclear imaging agents with the procedure, but this has created a barrier for those who require pricier new drugs.
Arizona-based Southwest Diagnostic Imaging said the decision is effective immediately, with its 19 locations now considered out-of-network for those using UHC health plans.
Both tirzepatide (Mounjaro) and semaglutide (Ozempic) have made headlines in recent months for their benefits in broad patient populations. This new analysis compared the two medications in obese/overweight adults with and without type 2 diabetes.
